MicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration

Advanced Drug Delivery Reviews

Volumn 88, Issue , 2015, Pages 92-107

  Ong, Siew Min ^a   Biswas, Subhra K ^a   Wong, Siew Cheng ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Foreign body reaction; Immune response; Macrophages; MiRNAs; Osteolysis; Pro inflammatory cytokines; TLR

Indexed keywords

IMMUNE SYSTEM; INTEGRATION; MACROPHAGES; RNA; TISSUE REGENERATION;

FOREIGN BODY REACTIONS; IMMUNE RESPONSE; MIRNAS; OSTEOLYSIS; PRO-INFLAMMATORY CYTOKINES;

IMPLANTS (SURGICAL);

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; CRYOPYRIN; INFLAMMASOME; MICRORNA; POLYETHYLENEIMINE; POLYGLACTIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; AUTACOID; BIOMATERIAL; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; CELL POLARITY; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FOREIGN BODY REACTION; GENE SILENCING; GENE THERAPY; GIANT CELL; HOST IMPLANT INTEGRATION; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; JOINT PROSTHESIS; MACROPHAGE FUNCTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM; BIOSYNTHESIS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; PHYSIOLOGY; PROSTHESES AND ORTHOSES; SIGNAL TRANSDUCTION;

BIOCOMPATIBLE MATERIALS; CARRIER PROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MICRORNAS; OSTEOLYSIS; PROSTHESES AND IMPLANTS; SIGNAL TRANSDUCTION;

EID: 84937517845     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.05.013     Document Type: Review

References (242)

1. Lodder A., Kamath M.V., Upton A.R., Armstrong D. Evaluation of the efficacy and performance of medical implants: a review. J. Long-Term Eff. Med. Implants 2010, 20:173-185.
2. Boehler R.M., Graham J.G., Shea L.D. Tissue engineering tools for modulation of the immune response. Biotechniques 2011, 51:239-254.
3. Baddour J.A., Sousounis K., Tsonis P.A. Organ repair and regeneration: an overview. Birth Defects Res. C Embryo Today 2012, 96:1-29.
4. Anderson J.M., McNally A.K. Biocompatibility of implants: lymphocyte/macrophage interactions. Semin. Immunopathol. 2011, 33:221-233.
5. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20:86-100.
6. Anderson J.M. Biological responses to materials. Annu. Rev. Mater. Res. 2001, 31:81-110.
7. Bryers J.D., Giachelli C.M., Ratner B.D. Engineering biomaterials to integrate and heal: the biocompatibility paradigm shifts. Biotechnol. Bioeng. 2012, 109:1898-1911.
8. Ratner B.D. The biocompatibility manifesto: biocompatibility for the twenty-first century. J. Cardiovasc. Transl. Res. 2011, 4:523-527.
9. Williams D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29:2941-2953.
10. Helton K.L., Ratner B.D., Wisniewski N.A. Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on sensor performance and the foreign body response-part I: theoretical framework. J. Diabetes Sci. Technol. 2011, 5:632-646.
11. Walboomers X.F., Croes H.J., Ginsel L.A., Jansen J.A. Microgrooved subcutaneous implants in the goat. J. Biomed. Mater. Res. 1998, 42:634-641.
12. Hallab N.J., Jacobs J.J. Biologic effects of implant debris. Bull. NYU Hosp. Jt. Dis. 2009, 67:182-188.
13. Simonis P., Dufour T., Tenenbaum H. Long-term implant survival and success: a 10-16-year follow-up of non-submerged dental implants. Clin. Oral Implants Res. 2010, 21:772-777.
14. Cobelli N., Scharf B., Crisi G.M., Hardin J., Santambrogio L. Mediators of the inflammatory response to joint replacement devices. Nat. Rev. Rheumatol. 2011, 7:600-608.
15. Thevenot P., Hu W., Tang L. Surface chemistry influences implant biocompatibility. Curr. Top. Med. Chem. 2008, 8:270-280.
16. Goodman S.B., Yao Z., Keeney M., Yang F. The future of biologic coatings for orthopaedic implants. Biomaterials 2013, 34:3174-3183.
17. Couto D.S., Perez-Breva L., Saraiva P., Cooney C.L. Lessons from innovation in drug-device combination products. Adv. Drug Deliv. Rev. 2012, 64:69-77.
18. Wu P., Grainger D.W. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006, 27:2450-2467.
19. Domb A.J., Wahid Khan Focal Controlled Drug Delivery 2014, Springer, US.
20. Mani G., Feldman M.D., Patel D., Agrawal C.M. Coronary stents: a materials perspective. Biomaterials 2007, 28:1689-1710.
21. Sonntag R., Reinders J., Kretzer J.P. What's next? Alternative materials for articulation in total joint replacement. Acta Biomater. 2012, 8:2434-2441.
22. Lee Y., Jeon K., Lee J.-T., Kim S., Kim V.N. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002, 21:4663-4670.
23. Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006, 25:6156-6162.
24. Khvorova A., Reynolds A., Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2002, 115:209-216.
25. Hutvágner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
26. Guo H.H., Ingolia N.T.N., Weissman J.S.J., Bartel D.P.D. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
27. Huntzinger E., Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 2011, 12:99-110.
28. Grimm D. Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev. 2009, 61:672-703.
29. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
30. Saraiya A.A., Li W., Wang C.C. Transition of a microRNA from repressing to activating translation depending on the extent of base pairing with the target. PLoS One 2013, 8. e55672.
31. Sheedy F.J., O'Neill L.A.J. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann. Rheum. Dis. 2008, 67:iii50-iii55.
32. Ha T.-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw. 2011, 11:135-154.
33. Li Y., Kowdley K.V. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 2012, 10:246-253.
34. Stoicea N., Wilson T., Chandrasekharand K., Bergese S.D. The Rrole of microRNAs as potential biomarkers in central nervous system disorders. Int. J. Clin. Anesthesiol. 2013, 1:1009-1010.
35. Rao D.D., Senzer N., Cleary M.A., Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther. 2009, 16:807-809.
36. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6:1130-1146.
37. Kubowicz P., Zelaszczyk D., Pekala E. RNAi in clinical studies. Curr. Med. Chem. 2013, 20:1801-1816.
38. Ozcan G., Ozpolat B., Coleman R.L., Sood A.K., Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 2015, 87:108-119.
39. Singh S., Narang A.S., Mahato R.I. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 2011, 28:2996-3015.
40. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
41. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
42. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56:1733-1741.
43. Bader A.G., Brown D., Stoudemire J., Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011, 18:1121-1126.
44. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9:775-789.
45. Tan P.-H., Pao Y.-Y., Cheng J.-K., Hung K.-C., Liu C.-C. MicroRNA-based therapy in pain medicine: current progress and future prospects. Acta Anaesthesiol. Taiwan. 2013, 51:171-176.
46. Li Y., Fan L., Liu S., Liu W., Zhang H., Zhou T., Wu D., Yang P., Shen L., Chen J., Jin Y. The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a. Biomaterials 2013, 34:5048-5058.
47. Ochi M., Nakasa T., Kamei G., Usman M.A., El Mahmoud H. Regenerative medicine in orthopedics using cells, scaffold, and microRNA. J. Orthop. Sci. 2014, 19:521-528.
48. van Rooij E., Olson E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 2012, 11:860-872.
49. Li L., Zhu D., Huang L., Zhang J., Bian Z., Chen X., Liu Y., Zhang C.-Y., Zen K. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS ONE 2011, 7. (e46957-e46957).
50. van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. Embo Mol. Med. 2014, 6:851-864.
51. Devalliere J., Chang W.G., Andrejecsk J.W., Abrahimi P., Cheng C.J., Jane-wit D., Saltzman W.M., Pober J.S. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J. 2014, 28:908-922.
52. Esau C.C., Monia B.P. Therapeutic potential for microRNAs. Adv. Drug Deliv. Rev. 2006, 59:101-114.
53. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
54. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
55. Selbach M., Schwanhäusser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
56. Jenney C.R., Anderson J.M. Adsorbed serum proteins responsible for surface dependent human macrophage behavior. J. Biomed. Mater. Res. 2000, 49:435-447.
57. Tang L., Hu W. Molecular determinants of biocompatibility. Expert Rev. Med. Devices 2005, 2:493-500.
58. Kourtzelis I., Rafail S., DeAngelis R.A., Foukas P.G., Ricklin D., Lambris J.D. Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. FASEB J. 2013, 27:2768-2776.
59. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 2007, 44:82-94.
60. Gorbet M.B., Sefton M.V. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004, 25:5681-5703.
61. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
62. Collier T.O., Anderson J.M. Protein and surface effects on monocyte and macrophage adhesion, maturation, and survival. J. Biomed. Mater. Res. 2002, 60:487-496.
63. Brodbeck W.G., Anderson J.M. Giant cell formation and function. Curr. Opin. Hematol. 2009, 16:53-57.
64. McNally A.K., Jones J.A., Macewan S.R., Colton E., Anderson J.M. Vitronectin is a critical protein adhesion substrate for IL-4-induced foreign body giant cell formation. J. Biomed. Mater. Res. A 2008, 86:535-543.
65. McNally A.K., Macewan S.R., Anderson J.M. Alpha subunit partners to beta1 and beta2 integrins during IL-4-induced foreign body giant cell formation. J. Biomed. Mater. Res. A 2007, 82:568-574.
66. Broughton G., Janis J.E., Attinger C.E. The basic science of wound healing. Plast. Reconstr. Surg. 2006, 117:12S-34S.
67. Brodbeck W.G., Voskerician G., Ziats N.P., Nakayama Y., Matsuda T., Anderson J.M. In vivo leukocyte cytokine mRNA responses to biomaterials are dependent on surface chemistry. J. Biomed. Mater. Res. A 2003, 64:320-329.
68. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
69. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003, 83:835-870.
70. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 2007, 127:526-537.
71. Zhang B.G., Myers D.E., Wallace G.G., Brandt M., Choong P.F. Bioactive coatings for orthopaedic implants-recent trends in development of implant coatings. Int. J. Mol. Sci. 2014, 15:11878-11921.
72. Wang P., Luo J., Du M., He C., Fan C., Zhong Y. Synthesis, characterization and blood compatibility studies of waterproof breathable polyurethanes. Sheng wu yi xue gong cheng xue za zhi=J. Biomed. Eng. = = Shengwu yixue gongchengxue zazhi 2005, 22:734-738.
73. Wang Y.X., Robertson J.L., Spillman W.B., Claus R.O. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm. Res. 2004, 21:1362-1373.
74. Jenney C.R., Anderson J.M. Adsorbed IgG: a potent adhesive substrate for human macrophages. J. Biomed. Mater. Res. 2000, 50:281-290.
75. Barbosa J.N., Barbosa M.A., Aguas A.P. Adhesion of human leukocytes to biomaterials: an in vitro study using alkanethiolate monolayers with different chemically functionalized surfaces. J. Biomed. Mater. Res. A 2003, 65:429-434.
76. Spijker H.T., Graaff R., Boonstra P.W., Busscher H.J., van Oeveren W. On the influence of flow conditions and wettability on blood material interactions. Biomaterials 2003, 24:4717-4727.
77. Casa L.D., Deaton D.H., Ku D.N. Role of high shear rate in thrombosis. J. Vasc. Surg. 2015, 61:1068-1080.
78. Rao P.J., Pelletier M.H., Walsh W.R., Mobbs R.J. Spine interbody implants: material selection and modification, functionalization and bioactivation of surfaces to improve osseointegration. Orthop. Surg. 2014, 6:81-89.
79. Macdonald M.L., Samuel R.E., Shah N.J., Padera R.F., Beben Y.M., Hammond P.T. Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. Biomaterials 2011, 32:1446-1453.
80. Fukano Y., Usui M.L., Underwood R.A., Isenhath S., Marshall A.J., Hauch K.D., Ratner B.D., Olerud J.E., Fleckman P. Epidermal and dermal integration into sphere-templated porous poly(2-hydroxyethyl methacrylate) implants in mice. J. Biomed. Mater. Res. A 2010, 94:1172-1186.
81. Underwood R.A., Usui M.L., Zhao G., Hauch K.D., Takeno M.M., Ratner B.D., Marshall A.J., Shi X., Olerud J.E., Fleckman P. Quantifying the effect of pore size and surface treatment on epidermal incorporation into percutaneously implanted sphere-templated porous biomaterials in mice. J. Biomed. Mater. Res. A 2011, 98:499-508.
82. Wagner V.E., Bryers J.D. Poly(ethylene glycol)-polyacrylate copolymers modified to control adherent monocyte-macrophage physiology: interactions with attaching Staphylococcus epidermidis or Pseudomonas aeruginosa bacteria. J. Biomed. Mater. Res. A 2004, 69:79-90.
83. Ratner B.D., Bryant S.J. Biomaterials: where we have been and where we are going. Annu. Rev. Biomed. Eng. 2004, 6:41-75.
84. Nie H., Wang C.-H. Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA. J. Control. Release 2007, 120:111-121.
85. Chew S.Y., Wen J., Yim E.K.F., Leong K.W. Sustained release of proteins from electrospun biodegradable fibers. Biomacromolecules 2005, 6:2017-2024.
86. Clark P.A., Moioli E.K., Sumner D.R., Mao J.J. Porous implants as drug delivery vehicles to augment host tissue integration. FASEB J. 2008, 22:1684-1693.
87. Cantón I., Mckean R., Charnley M., Blackwood K.A., Fiorica C., Ryan A.J., MacNeil S. Development of an Ibuprofen-releasing biodegradable PLA/PGA electrospun scaffold for tissue regeneration. Biotechnol. Bioeng. 2010, 105:396-408.
88. Vacanti N.M., Cheng H., Hill P.S., Guerreiro J.D.T., Dang T.T., Ma M., Watson S., Hwang N.S., Langer R., Anderson D.G. Localized delivery of dexamethasone from electrospun fibers reduces the foreign body response. Biomacromolecules 2012, 13:3031-3038.
89. Vargas E.T., do Vale Baracho N.C., de Brito J., de Queiroz A. Hyperbranched polyglycerol electrospun nanofibers for wound dressing applications. Acta Biomater. 2009, 6:1069-1078.
90. Kyriakides T.R., Hartzel T., Huynh G., Bornstein P. Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. Mol. Ther. 2001, 3:842-849.
91. Wang Y., Grainger D.W. Developing siRNA therapies to address osteoporosis. Ther. Deliv. 2013, 4:1239-1246.
92. Dang T.T.T., Bratlie K.M.K., Bogatyrev S.R.S., Chen X.Y.X., Langer R.R., Anderson D.G.D. Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response. Biomaterials 2011, 32:4464-4470.
93. Webber M.J., Matson J.B., Tamboli V.K., Stupp S.I. Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response. Biomaterials 2012, 33:6823-6832.
94. Mori R., Shaw T.J., Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J. Exp. Med. 2008, 205:43-51.
95. Wang Y., Tran K.K., Shen H., Grainger D.W. Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials 2012, 33:8540-8547.
96. Jay S.M., Skokos E., Laiwalla F., Krady M.M., Kyriakides T.R. Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. Am. J. Pathol. 2007, 171:632-640.
97. Takahashi H., Wang Y., Grainger D.W. Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation. J. Control. Release 2010, 147:400-407.
98. van Putten S.M., Wübben M., Hennink W.E., van Luyn M.J.A., Harmsen M.C. The downmodulation of the foreign body reaction by cytomegalovirus encoded interleukin-10. Biomaterials 2009, 30:730-735.
99. Rao A.J., Gibon E., Ma T., Yao Z., Smith R.L., Goodman S.B. Revision joint replacement, wear particles, and macrophage polarization. Acta Biomater. 2012, 8:2815-2823.
100. Rao A.J., Nich C., Dhulipala L.S., Gibon E., Valladares R., Zwingenberger S., Smith R.L., Goodman S.B. Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium. J. Biomed. Mater. Res. A 2013, 101:1926-1934.
101. Sargeant A., Goswami T. Pathophysiological aspects of hip implants. J. Surg. Orthop. Adv. 2006, 15:111-112.
102. Maitra R., Clement C.C., Crisi G.M., Cobelli N., Santambrogio L. Immunogenecity of modified alkane polymers is mediated through TLR1/2 activation. PLoS One 2008, 3:e2438.
103. Zhao D.S., Ma G.F., Selenius M., Salo J., Pikkarainen T., Konttinen Y.T. Ectopic expression of macrophage scavenger receptor MARCO in synovial membrane-like interface tissue in aseptic loosening of total hip replacement implants. J. Biomed. Mater. Res. A 2010, 92:641-649.
104. Chen Y., Pikkarainen T., Elomaa O., Soininen R., Kodama T., Kraal G., Tryggvason K. Defective microarchitecture of the spleen marginal zone and impaired response to a thymus-independent type 2 antigen in mice lacking scavenger receptors MARCO and SR-A. J. Immunol. 2005, 175:8173-8180.
105. Jozefowski S., Arredouani M., Sulahian T., Kobzik L. Disparate regulation and function of the class A scavenger receptors SR-AI/II and MARCO. J. Immunol. 2005, 175:8032-8041.
106. Reno F., Bracco P., Costa L., Cannas M. Cytotoxicity and MMP-9 activation induced in human mononuclear cells by UHMWPE oxidation. Biomaterials 2002, 23:3645-3650.
107. Bosetti M., Zanardi L., Bracco P., Costa L., Cannas M. In vitro evaluation of the inflammatory activity of ultra-high molecular weight polyethylene. Biomaterials 2003, 24:1419-1426.
108. Willert H.G., Buchhorn G.H., Fayyazi A., Flury R., Windler M., Koster G., Lohmann C.H. Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study. J. Bone Joint Surg. Am. 2005, 87:28-36.
109. Huber M., Reinisch G., Zenz P., Zweymuller K., Lintner F. Postmortem study of femoral osteolysis associated with metal-on-metal articulation in total hip replacement: an analysis of nine cases. J. Bone Joint Surg. Am. Vol. 2010, 92:1720-1731.
110. Goodman S.B., Ma T. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 2010, 31:5045-5050.
111. Kanaji A., Caicedo M.S., Virdi A.S., Sumner D.R., Hallab N.J., Sena K. Co-Cr-Mo alloy particles induce tumor necrosis factor alpha production in MLO-Y4 osteocytes: a role for osteocytes in particle-induced inflammation. Bone 2009, 45:528-533.
112. Smith R.A., Maghsoodpour A., Hallab N.J. In vivo response to cross-linked polyethylene and polycarbonate-urethane particles. J. Biomed. Mater. Res. A 2010, 93:227-234.
113. Lenz R., Mittelmeier W., Hansmann D., Brem R., Diehl P., Fritsche A., Bader R. Response of human osteoblasts exposed to wear particles generated at the interface of total hip stems and bone cement. J. Biomed. Mater. Res. A 2009, 89:370-378.
114. Nich C., Takakubo Y., Pajarinen J., Ainola M., Salem A., Sillat T., Rao A.J., Raska M., Tamaki Y., Takagi M., Konttinen Y.T., Goodman S.B., Gallo J. Macrophages-key cells in the response to wear debris from joint replacements. J. Biomed. Mater. Res. A 2013, 101:3033-3045.
115. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediat. Inflamm. 2010, 2010.
116. Ingham E., Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005, 26:1271-1286.
117. Henson P.M. The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J. Immunol. 1971, 107:1547-1557.
118. Freeman T.A., Parvizi J., Della Valle C.J., Steinbeck M.J. Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair 2009, 2:5.
119. O'Neill L.A. Immunology. How frustration leads to inflammation. Science 2008, 320:619-620.
120. Caicedo M.S., Desai R., McAllister K., Reddy A., Jacobs J.J., Hallab N.J. Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J. Orthop. Res. 2009, 27:847-854.
121. Lamkanfi M., Dixit V.M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 2009, 227:95-105.
122. Maitra R., Clement C.C., Scharf B., Crisi G.M., Chitta S., Paget D., Purdue P.E., Cobelli N., Santambrogio L. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol. Immunol. 2009, 47:175-184.
123. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
124. Chiu R., Ma T., Smith R.L., Goodman S.B. Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro. J. Biomed. Mater. Res. A 2009, 89:242-247.
125. Goodman S.B., Gomez Barrena E., Takagi M., Konttinen Y.T. Biocompatibility of total joint replacements: a review. J. Biomed. Mater. Res. A 2009, 90:603-618.
126. Konttinen Y.T., Zhao D., Beklen A., Ma G., Takagi M., Kivela-Rajamaki M., Ashammakhi N., Santavirta S. The microenvironment around total hip replacement prostheses. Clin. Orthop. Relat. Res. 2005, 28-38.
127. Nawrocki B., Polette M., Burlet H., Birembaut P., Adnet J.J. Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1999, 14:288-294.
128. Takei I., Takagi M., Santavirta S., Ida H., Ishii M., Ogino T., Ainola M., Konttinen Y.T. Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints. J. Biomed. Mater. Res. 2000, 52:613-620.
129. D'Lima D.D., Hermida J.C., Chen P.C., Colwell C.W. Polyethylene cross-linking by two different methods reduces acetabular liner wear in a hip joint wear simulator. J. Orthop. Res. 2003, 21:761-766.
130. Ingram J.H., Stone M., Fisher J., Ingham E. The influence of molecular weight, crosslinking and counterface roughness on TNF-alpha production by macrophages in response to ultra high molecular weight polyethylene particles. Biomaterials 2004, 25:3511-3522.
131. Kop A.M., Whitewood C., Johnston D.J. Damage of oxinium femoral heads subsequent to hip arthroplasty dislocation three retrieval case studies. J. Arthroplast. 2007, 22:775-779.
132. Mazzocchi M., Bellosi A. On the possibility of silicon nitride as a ceramic for structural orthopaedic implants. Part I: processing, microstructure, mechanical properties, cytotoxicity. J. Mater. Sci. Mater. Med. 2008, 19:2881-2887.
133. Alakoski E., Tiainen V.M., Soininen A., Konttinen Y.T. Load-bearing biomedical applications of diamond-like carbon coatings-current status. Open Orthop. J. 2008, 2:43-50.
134. Raimondi M.T., Pietrabissa R. The in-vivo wear performance of prosthetic femoral heads with titanium nitride coating. Biomaterials 2000, 21:907-913.
135. Brown B.N., Ratner B.D., Goodman S.B., Amar S., Badylak S.F. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials 2012, 33:3792-3802.
136. Kao W.J. Evaluation of protein-modulated macrophage behavior on biomaterials: designing biomimetic materials for cellular engineering. Biomaterials 1999, 20:2213-2221.
137. Kou P.M., Babensee J.E. Macrophage and dendritic cell phenotypic diversity in the context of biomaterials. J. Biomed. Mater. Res. A 2011, 96:239-260.
138. Ferrante C.J., Leibovich S.J. Regulation of macrophage polarization and wound healing. Adv. Wound Care 2012, 1:10-16.
139. Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports 2014, 6:13.
140. Biswas S.K.S., Mantovani A.A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
141. Pajarinen J., Kouri V.P., Jamsen E., Li T.F., Mandelin J., Konttinen Y.T. The response of macrophages to titanium particles is determined by macrophage polarization. Acta Biomater. 2013, 9:9229-9240.
142. Wang Y., Wu N.N., Mou Y.Q., Chen L., Deng Z.L. Inhibitory effects of recombinant IL-4 and recombinant IL-13 on UHMWPE-induced bone destruction in the murine air pouch model. J. Surg. Res. 2013, 180:e73-e81.
143. Madden L.R., Mortisen D.J., Sussman E.M., Dupras S.K., Fugate J.A., Cuy J.L., Hauch K.D., Laflamme M.A., Murry C.E., Ratner B.D. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15211-15216.
144. Brown B.N., Londono R., Tottey S., Zhang L., Kukla K.A., Wolf M.T., Daly K.A., Reing J.E., Badylak S.F. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater. 2012, 8:978-987.
145. Paul N.E., Skazik C., Harwardt M., Bartneck M., Denecke B., Klee D., Salber J., Zwadlo-Klarwasser G. Topographical control of human macrophages by a regularly microstructured polyvinylidene fluoride surface. Biomaterials 2008, 29:4056-4064.
146. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.-Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
147. Hulsmans M., Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc. Res. 2013, 100:7-18.
148. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
149. Katare R., Riu F., Mitchell K., Gubernator M., Campagnolo P., Cui Y., Fortunato O., Avolio E., Cesselli D., Beltrami A.P., Angelini G., Emanueli C., Madeddu P. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ. Res. 2011, 109:894-906.
150. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J. Control. Release 2013, 172:962-974.
151. Graff J.W., Dickson A.M., Clay G., McCaffrey A.P., Wilson M.E. Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 2012, 287:21816-21825.
152. Nahid M.A., Pauley K.M., Satoh M., Chan E.K.L. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J. Biol. Chem. 2009, 284:34590-34599.
153. Sheedy F.J., Palsson-McDermott E., Hennessy E.J., Martin C., O'Leary J.J., Ruan Q., Johnson D.S., Chen Y., O'Neill L.A.J. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2010, 11:141-147.
154. Huang H.-C., Yu H.-R., Huang L.-T., Huang H.-C., Chen R.-F., Lin I.-C., Ou C.-Y., Hsu T.-Y., Yang K.D. miRNA-125b regulates TNF-α production in CD14+ neonatal monocytes via post-transcriptional regulation. J. Leukoc. Biol. 2012, 92:171-182.
155. Banerjee S., Xie N., Cui H., Tan Z., Yang S., Icyuz M., Abraham E., Liu G. MicroRNA let-7c regulates macrophage polarization. J. Immunol. (Baltimore, Md.: 1950) 2013, 190:6542-6549.
156. Litvak V., Ramsey S.A., Rust A.G., Zak D.E., Kennedy K.A., Lampano A.E., Nykter M., Shmulevich I., Aderem A. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat. Immunol. 2009, 10:437-443.
157. He X., Jing Z., Cheng G. MicroRNAs: new regulators of Toll-like receptor signalling pathways. BioMed Res. Int. 2013, 2014. (945169-945169).
158. Goodman S.B., Gibon E., Pajarinen J., Lin T.-H., Keeney M., Ren P.-G., Nich C., Yao Z., Egashira K., Yang F., Konttinen Y.T. Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement. J. R. Soc. Interface 2014, 11. (20130962-20130962).
159. Pearl J.I., Ma T., Irani A.R., Huang Z., Robinson W.H., Smith R.L., Goodman S.B. Role of the Toll-like receptor pathway in the recognition of orthopedic implant wear-debris particles. Biomaterials 2011, 32:5535-5542.
160. Liu G.G., Friggeri A.A., Yang Y.Y., Park Y.-J.Y., Tsuruta Y.Y., Abraham E.E. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Audio, Trans. IRE Prof. Group on 2009, 106:15819-15824.
161. Zhu Q.-Y.Q., Liu Q.Q., Chen J.-X.J., Lan K.K., Ge B.-X.B. MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages. J. Immunol. (Baltimore, Md.: 1950) 2010, 185:7435-7442.
162. Hou J., Wang P., Lin L., Liu X., Ma F., An H., Wang Z., Cao X. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 2009, 183:2150-2158.
163. Tang Y., Luo X., Cui H., Ni X., Yuan M., Guo Y., Huang X., Zhou H., de Vries N., Tak P.P., Chen S., Shen N. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60:1065-1075.
164. Das A., Ganesh K., Khanna S., Sen C.K., Roy S. Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. J. Immunol. 2014, 192:1120-1129.
165. Lai L., Song Y., Liu Y., Chen Q., Han Q., Chen W., Pan T., Zhang Y., Cao X., Wang Q. MicroRNA-92a negatively regulates Toll-like receptor (TLR)-triggered inflammatory response in macrophages by targeting MKK4 kinase. J. Biol. Chem. 2013, 288:7956-7967.
166. Philippe L., Alsaleh G., Suffert G., Meyer A., Georgel P., Sibilia J., Wachsmann D., Pfeffer S. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J. Immunol. 2012, 188:454-461.
167. Benakanakere M.R., Li Q., Eskan M.A., Singh A.V., Zhao J., Galicia J.C., Stathopoulou P., Knudsen T.B., Kinane D.F. Modulation of TLR2 protein expression by miR-105 in human oral keratinocytes. J. Biol. Chem. 2009, 284:23107-23115.
168. Chen X.-M., Splinter P.L., O'Hara S.P., LaRusso N.F. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J. Biol. Chem. 2007, 282:28929-28938.
169. Bauernfeind F., Rieger A., Schildberg F.A., Knolle P.A., Schmid-Burgk J.L., Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. (Baltimore, Md.: 1950) 2012, 189:4175-4181.
170. Haneklaus M., Gerlic M., Kurowska-Stolarska M., Rainey A.-A., Pich D., McInnes I.B., Hammerschmidt W., O'Neill L.A.J., Masters S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J. Immunol. 2012, 189:3795-3799.
171. Bandyopadhyay S., Lane T., Venugopal R., Parthasarathy P.T., Cho Y., Galam L., Lockey R., Kolliputi N. MicroRNA-133a-1 regulates inflammasome activation through uncoupling protein-2. Biochem. Biophys. Res. Commun. 2013, 439:407-412.
172. Dou C., Zhang C., Kang F., Yang X., Jiang H., Bai Y., Xiang J., Xu J., Dong S. MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim. Biophys. Acta 2014, 1839:1084-1096.
173. Sissons J.R., Peschon J.J., Schmitz F., Suen R., Gilchrist M., Aderem A. Cutting edge: microRNA regulation of macrophage fusion into multinucleated giant cells. J. Immunol. (Baltimore, Md.: 1950) 2012, 189:23-27.
174. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., Morita K., Ninomiya K., Suzuki T., Miyamoto K., Oike Y., Takeya M., Toyama Y., Suda T. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 2005, 202:345-351.
175. Boehler R.M., Kuo R., Shin S., Goodman A.G., Pilecki M.A., Gower R.M., Leonard J.N., Shea L.D. Lentivirus delivery of IL-10 to promote and sustain macrophage polarization towards an anti-inflammatory phenotype. Biotechnol. Bioeng. 2014, 111:1210-1221.
176. Liu Y., Chen Q., Song Y., Lai L., Wang J., Yu H., Cao X., Wang Q. MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett. 2011, 585:1963-1968.
177. Ma F., Liu X., Li D., Wang P., Li N., Lu L., Cao X. MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J. Immunol. (Baltimore, Md.: 1950) 2010, 184:6053-6059.
178. Quinn S.R., O'Neill L.A. The role of microRNAs in the control and mechanism of action of IL-10. Curr. Top. Microbiol. Immunol. 2013, 380:145-155.
179. Lin L., Hou J., Ma F., Wang P., Liu X., Li N., Wang J., Wang Q., Cao X. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J. Immunol. 2013, 191:3896-3904.
180. Rossato M., Curtale G., Tamassia N., Castellucci M., Mori L., Gasperini S., Mariotti B., De Luca M., Mirolo M., Cassatella M.A., Locati M., Bazzoni F. IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3101-E3110.
181. Curtale G., Mirolo M., Renzi T.A., Rossato M., Bazzoni F., Locati M. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b 2013, 110:11499-11504.
182. McCoy C.E., Sheedy F.J., Qualls J.E., Doyle S.L., Quinn S.R., Murray P.J., O'Neill L.A.J. IL-10 inhibits miR-155 induction by toll-like receptors. J. Biol. Chem. 2010, 285:20492-20498.
183. Schaefer J.S., Montufar-Solis D., Vigneswaran N., Klein J.R. Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10-/- mice precedes expression in the colon. J. Immunol. 2011, 187:5834-5841.
184. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., Lovat F., Fadda P., Mao C., Nuovo G.J., Zanesi N., Crawford M., Ozer G.H., Wernicke D., Alder H., Caligiuri M.A., Nana-Sinkam P., Perrotti D., Croce C.M. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2110-E2116.
185. Sepp-Lorenzino L., Ruddy M. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin. Pharmacol. Ther. 2008, 84:628-632.
186. Butler M., Hayes C.S., Chappell A., Murray S.F., Yaksh T.L., Hua X.-Y. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 2004, 131:705-715.
187. Danis R., Criswell M., Orge F., Wancewicz E., Stecker K., Henry S., Monia B. Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr. Eye Res. 2002, 26:45-54.
188. Cook P.D. Medicinal chemistry of antisense oligonucleotides-future opportunities. Anticancer Drug Des. 1991, 6:585-607.
189. Thorsen S.B., Obad S., Jensen N.F., Stenvang J., Kauppinen S. The therapeutic potential of microRNAs in cancer. Cancer J. (Sudbury, Mass.) 2012, 18:275-284.
190. Chen P.Y., Weinmann L., Gaidatzis D., Pei Y., Zavolan M., Tuschl T., Meister G. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.
191. Reynolds A., Anderson E.M., Vermeulen A., Fedorov Y., Robinson K., Leake D., Karpilow J., Marshall W.S., Khvorova A. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006, 12:988-993.
192. Peacock H., Fucini R.V., Jayalath P., Ibarra-Soza J.M., Haringsma H.J., Flanagan W.M., Willingham A., Beal P.A. Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic. RNA 2011, 133:9200-9203.
193. Trang P., Medina P.P., Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Homer R., Brown D., Bader A.G., Weidhaas J.B., Slack F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587.
194. Kota J., Chivukula R.R., O'Donnell K.A., Donnell E.A.Wentzel, Montgomery C.L., Hwang H.-W., Chang T.-C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
195. Miyazaki Y., Adachi H., Katsuno M., Minamiyama M., Jiang Y.-M., Huang Z., Doi H., Matsumoto S., Kondo N., Iida M., Tohnai G., Tanaka F., Muramatsu S.-i., Sobue G. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat. Med. 2012, 18:1136-1141.
196. Mingozzi F., Maus M.V., Hui D.J., Sabatino D.E., Murphy S.L., Rasko J.E.J., Ragni M.V., Manno C.S., Sommer J., Jiang H., Pierce G.F., Ertl H.C.J., High K.A. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 2007, 13:419-422.
197. Mease P.J., Wei N., Fudman E.J., Kivitz A.J., Schechtman J., Trapp R.G., Hobbs K.F., Greenwald M., Hou A., Bookbinder S.A., Graham G.E., Wiesenhutter C.W., Willis L., Ruderman E.M., Forstot J.Z., Maricic M.J., Dao K.H., Pritchard C.H., Fiske D.N., Burch F.X., Prupas H.M., Anklesaria P., Heald A.E. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J. Rheumatol. 2010, 37:692-703.
198. Broderick J.A., Zamore P.D. MicroRNA therapeutics. Gene Ther. 2011, 18:1104-1110.
199. Lennox K.A., Behlke M.A. A direct comparison of anti-microRNA oligonucleotide potency. Pharm. Res. 2010, 27:1788-1799.
200. Lennox K.A., Behlke M.A. Chemical modification and design of anti-miRNA. Oligonucleotides 2011, 18:1111-1120.
201. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
202. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Röhl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.-P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
203. Krützfeldt J., Kuwajima S., Braich R., Rajeev K.G., Pena J., Tuschl T., Manoharan M., Stoffel M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2006, 35:2885-2892.
204. Davis S., Lollo B., Freier S., Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006, 34:2294-2304.
205. Ørom U.A., Kauppinen S., Lund A.H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006, 372:137-141.
206. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
207. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
208. Worm J., Stenvang J., Petri A., Frederiksen K.S., Obad S., Elmén J., Hedtjärn M., Straarup E.M., Hansen J.B., Kauppinen S. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res. 2009, 37:5784-5792.
209. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
210. Vickers K.C.K., Remaley A.T.A. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012, 23:91-97.
211. Dass C.R. Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv. 2002, 9:169-180.
212. Dritschilo A.A., Huang C.H.C., Rudin C.M.C., Marshall J.J., Collins B.B., Dul J.L.J., Zhang C.C., Kumar D.D., Gokhale P.C.P., Ahmad A.A., Ahmad I.I., Sherman J.W.J., Kasid U.N.U. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 2006, 12:1251-1259.
213. Pramanik D., Campbell N.R., Karikari C., Chivukula R., Kent O.A., Mendell J.T., Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 2011, 10:1470-1480.
214. Tian T., Wang Y., Wang H., Zhu Z., Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J. Cell. Biochem. 2010, 111:488-496.
215. Montecalvo A., Larregina A.T., Shufesky W.J., Stolz D.B., Sullivan M.L.G., Karlsson J.M., Baty C.J., Gibson G.A., Erdos G., Wang Z., Milosevic J., Tkacheva O.A., Divito S.J., Jordan R., Lyons-Weiler J., Watkins S.C., Morelli A.E. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
216. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
217. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
218. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., Weidhaas J.B., Bader A.G., Slack F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19:1116-1122.
219. Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 2013, 577.
220. Cubillos-Ruiz J.R., Engle X., Scarlett U.K., Martinez D., Barber A., Elgueta R., Wang L., Nesbeth Y., Durant Y., Gewirtz A.T., Sentman C.L., Kedl R., Conejo-Garcia J.R. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 2009, 119:2231-2244.
221. Höbel S., Aigner A. Polyethylenimines for siRNA and miRNA delivery in vivo. A direct comparison of anti-microRNA oligonucleotide potency 2013, 5:484-501.
222. Ibrahim A.F., Weirauch U., Thomas M., Grunweller A., Hartmann R.K., Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71:5214-5224.
223. Cubillos-Ruiz J., Sempere L., Conejo-Garcia J. Good things come in small packages: therapeutic anti-tumor immunity induced by microRNA nanoparticles. Oncoimmunology 2012, 1:968-970.
224. Blum J.S., Saltzman W.M. High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J. Control. Release 2008, 129:66-72.
225. Uchegbu I.F. Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery. Expert Opin. Drug Deliv. 2006, 3:629-640.
226. Babar I.A., Cheng C.J., Booth C.J., Liang X., Weidhaas J.B., Saltzman W.M., Slack F.J. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1695-E1704.
227. Shen J., Xu R., Mai J., Kim H.-C., Guo X., Qin G., Yang Y., Wolfram J., Mu C., Xia X., Gu J., Liu X., Mao Z.-W., Ferrari M., Shen H. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 2013, 7:9867-9880.
228. Wang H., Chiu M., Xie Z., Chiu M., Liu Z., Chen P., Liu S., Byrd J.C., Muthusamy N., Garzon R., Croce C.M., Marcucci G., Chan K.K. Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. Mol. Pharm. 2012, 9:1638-1644.
229. Orsi S., Guarnieri D., De Capua A., Netti P.A. Gene-activated and cell-migration guiding PEG matrices based on three dimensional patterning of RGD peptides and DNA complexes. Acta Biomater. 2012, 8:3228-3240.
230. Tierney E.G., Duffy G.P., Cryan S.-A., Curtin C.M., O'Brien F.J. Non-viral gene-activated matrices: next generation constructs for bone repair. Organogenesis 2012, 9:22-28.
231. Tierney E.G., McSorley K., Hastings C.L., Cryan S.-A., O'Brien T., Murphy M.J., Barry F.P., O'Brien F.J., Duffy G.P. High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix. J. Control. Release 2013, 165:173-182.
232. Son J.S., Kim K.-H., Kwon T.-Y. Drug delivery from titanium surface using biodegradable nanoparticle carriers. Mater. Lett. 2012, 89:129-132.
233. Son J.S., Choi Y.-A., Park E.-K., Kwon T.-Y., Kim K.-H., Lee K.-B. Drug delivery from hydroxyapatite-coated titanium surfaces using biodegradable particle carriers. J. Biomed. Mater. Res. B Appl. Biomater. 2013, 101:247-257.
234. Liu L., Song L.-N., Yang G.-L., Zhao S.-F., He F.-m. Fabrication, characterization, and biological assessment of multilayer DNA coatings on sandblasted-dual acid etched titanium surface. J. Biomed. Mater. Res. A 2011, 97:300-310.
235. Jiang Q.-h., Liu L., Peel S., Yang G.-L., Zhao S.-F., He F.-m. Bone response to the multilayer BMP-2 gene coated porous titanium implant surface. Clin. Oral Implants Res. 2013, 24:853-861.
236. Sharma A., Kumar M., Aich J., Hariharan M., Brahmachari S.K., Agrawal A., Ghosh B. Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc. Natl. Acad. Sci. 2009, 106:5761-5766.
237. Xie N., Cui H., Banerjee S., Tan Z., Salomao R., Fu M., Abraham E., Thannickal V.J., Liu G. miR-27a regulates inflammatory response of macrophages by targeting IL-10. J. Immunol. (Baltimore, Md.: 1950) 2014, 193:327-334.
238. Chen Q.Q., Wang H.H., Liu Y.Y., Song Y.Y., Lai L.L., Han Q.Q., Cao X.X., Wang Q.Q. Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1β production in macrophages by targeting STAT3. PLoS ONE 2011, 7. (e42971-e42971).
239. Hutchison E.R., Kawamoto E.M., Taub D.D., Lal A., Abdelmohsen K., Zhang Y., Wood W.H., Lehrmann E., Camandola S., Becker K.G., Gorospe M., Mattson M.P. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 2013, 61:1018-1028.
240. Rosenberger C.M., Podyminogin R.L., Navarro G., Zhao G.-W., Askovich P.S., Weiss M.J., Aderem A. miR-451 regulates dendritic cell cytokine responses to influenza infection. J. Immunol. (Baltimore, Md.: 1950) 2012, 189:5965-5975.
241. El Gazzar M.M., Church A.A., Liu T.T., McCall C.E.C. MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming. J. Leukoc. Biol. 2011, 90:509-519.
242. Li L., Wei Z., Zhou Y., Gao F., Jiang Y., Yu L., Zheng H., Tong W., Yang S., Shan T., Liu F., Xia T., Tong G. Host miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by upregulating type I interferons. Virus Res. 2015, 195:86-94.